Merck & Co. stock gains as Guggenheim raises price target on oncology optimism

Published on 09/09/2026 at 14:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck & Co. stock is trading near its 52-week high after Guggenheim lifted its price target to 170.00 dollars on September 8, 2026, citing melanoma vaccine prospects. The shares closed at 148.44 dollars on September 8, 2026, with a market cap of 366.23 billion dollars.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co., Inc. stock (ISIN US58933Y1055) is trading close to its recent 52-week high after Guggenheim raised its price target to 170.00 dollars on September 8, 2026, highlighting strong oncology growth potential from the company’s melanoma cancer vaccine collaboration with Moderna.GuruFocus reports that this new target represents a 16.44 percent increase from Guggenheim’s previous target of 146.00 dollars, underscoring renewed confidence in Merck’s long-term oncology pipeline.

Analysts lift targets as stock nears 52-week high

According to GuruFocus on September 8, 2026, Guggenheim maintained its Buy rating on Merck & Co. and raised the price target from 146.00 dollars to 170.00 dollars, a jump of 24.00 dollars or 16.44 percent, reflecting increased conviction in the value of Merck’s melanoma vaccine program in partnership with Moderna.

Merck shares have been trading close to their 52-week high in recent sessions: on September 4, 2026, the stock closed at 150.33 dollars against a 52-week high of 156.92 dollars reached on August 25, 2026, leaving it only about 4 percent below that peak, as highlighted by Yahoo Finance.

As of the latest completed trading day, September 8, 2026, Merck & Co. closed at 148.44 dollars on the New York Stock Exchange, down 1.26 percent from the prior close of 150.37 dollars, with an intraday high of 149.60 dollars and a low of 146.28 dollars; the session volume reached 11.18 million shares and the market capitalization stood at 366.23 billion dollars.MarketBeat notes that this still leaves the stock only a few percentage points below the late-August high.

Recent earnings and guidance frame the valuation debate

Merck’s current valuation comes against the backdrop of mixed recent earnings and updated guidance. As finanzen.ch summarizes, Merck presented figures for the quarter ended June 30, 2026 (Q2/2026) in a report released on August 4, 2026, posting an earnings per share (EPS) loss of minus 0.54 dollars for the quarter, compared with market expectations that had pointed to a profit.

At the same time, Merck has issued full-year 2026 guidance that sets EPS in a range of 2.660 to 2.760 dollars, according to a recent analyst overview by MarketBeat. This guidance frames the market’s expectations for Merck’s earnings recovery after the Q2/2026 loss and provides a quantitative yardstick against which the raised price targets and current valuation are assessed.

Consensus estimates have shifted in recent weeks: Yahoo Finance reports that estimates for Merck’s 2026 EPS have been revised down from 4.31 dollars per share to 2.97 dollars per share over the past 60 days, while 2027 EPS estimates have eased from 9.85 dollars to 9.66 dollars per share. For investors, this downward revision in near-term earnings expectations is a key counterweight to the optimism on long-term oncology growth.

Dividend, analyst consensus and risk factors

Merck & Co. complements its growth story with a steady shareholder return policy. According to MarketBeat, the company recently confirmed a quarterly dividend of 0.85 dollars per share to be paid on October 7, 2026, to shareholders of record on September 15, 2026; this corresponds to an annualized dividend of 3.40 dollars per share and a yield of about 2.3 percent at recent price levels, with the current dividend payout ratio reported at 272.00 percent.

Analyst sentiment remains broadly positive. Based on data compiled by MarketBeat on September 9, 2026, Merck & Co. currently carries a consensus rating of Moderate Buy with a consensus price target of 149.80 dollars, which is only slightly above the latest close of 148.44 dollars. In this context, Guggenheim’s new 170.00-dollar target stands clearly above the average, signaling a more aggressive view on upside potential compared with the broader analyst community.

Risk factors are also present in the current narrative. The Q2/2026 EPS loss of minus 0.54 dollars per share and the downward revision of 2026 earnings estimates from 4.31 dollars to 2.97 dollars per share over a 60-day period, as cited by Yahoo Finance, underscore that near-term profitability is under pressure even as long-term oncology prospects remain promising. For investors, the balance between a rich valuation near the 52-week high and earnings risk is central to the investment case.

Merck & Co. stock price and trading context

Merck & Co. stock is listed on the New York Stock Exchange under the ticker MRK, and the NYSE quote in United States dollars serves as the primary reference price. As of the close on September 8, 2026, the shares finished at 148.44 dollars on the NYSE, with a market capitalization of 366.23 billion dollars and volume of 11.18 million shares recorded for that session.MarketBeat shows that this closing level is modestly below the recent 52-week high of 156.92 dollars reached on August 25, 2026, indicating that Merck & Co. stock remains in the upper region of its one-year trading range.